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Abstract. 1 
Background: Among patients with cirrhosis, only those determined to be at risk for 2 
hepatocellular carcinoma (HCC) should undergo surveillance. However, little is known about 3 
how different aetiologies of cirrhosis affect risk for HCC. 4 
 5 
Aim: To quantify the cumulative incidence of HCC among a representative population of people 6 
with cirrhosis of the liver of varying aetiology. 7 
 8 
Methods: We identified subjects with hepatic cirrhosis from the UK’s General Practice Research 9 
Database (1987–2006). Diagnoses of HCC were obtained from linked national cancer registries 10 
(1971–2006). Cox proportional hazards regression was used to estimate hazard ratios. The 11 
predicted 10-year cumulative incidence of HCC for each aetiology of cirrhosis was estimated 12 
while accounting for competing risks of death from any cause and liver transplant. 13 
 14 
Results: Among 3107 people with cirrhosis the adjusted relative risk of HCC was increased 2- to 15 
3-fold among people with viral and autoimmune/metabolic aetiologies, compared to those with 16 
alcohol-associated cirrhosis.  The 10-year predicted cumulative incidence estimates of HCC for 17 
each aetiology were: alcohol, 1.2%; chronic viral hepatitis 4.0%; autoimmune or metabolic 18 
disease 3.2%; and cryptogenic 1.1%.  19 
 20 
Conclusions: In a population-based study in the UK, people with cirrhosis have an estimated 21 
cumulative 10-year incidence of HCC of 4% or lower. Cumulative incidence varies with 22 
aetiology such that individuals with alcohol or cryptogenic cirrhosis have the lowest risk for 23 
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HCC. These findings provide important information for cost-effectiveness analyses of HCC 1 
surveillance. 2 
 3 
 4 
  5 
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Introduction 1 
Surveillance for hepatocellular carcinoma (HCC) has been suggested by some as an explicit 2 
indicator of quality of care in patients with cirrhosis1.  It remains however a highly controversial 3 
topic and a key aspect of such surveillance activities is whether or not they are cost-effective2, 3.  4 
It is self-evident that the incidence of HCC critically impacts on whether surveillance is cost-5 
effective, and guidance from the American Association for the Study of Liver Diseases 6 
(AASLD) based on studies evaluating cost-effectiveness4-6 recommends that surveillance should 7 
only be undertaken in those whose risk of HCC is 1.5% per year or greater (or in hepatitis B 8 
0.2% or greater)7.  While cirrhosis is the most common underlying condition associated with 9 
HCC, the incidence of HCC in cirrhosis due to different aetiologies is not fully known7.  Whilst 10 
the most recent AASLD guidance suggests that the thresholds for HCC incidence to be cost-11 
effective are exceeded in cirrhosis due to hepatitis B or C, primary biliary cirrhosis – now known 12 
as Primary Biliary Cholangitis (PBC), genetic haemochromatosis and alpha-1 antitrypsin 13 
deficiency, it is explicitly recognized in this guidance that the risk of HCC is not accurately 14 
known in many relevant groups. 15 
 16 
There is limited evidence to support the reported incidence of HCC; which may explain some of 17 
the documented lack of uptake of these guidelines8.  The available evidence is based principally 18 
on studies conducted in tertiary care centers on a small scale 9-13.  These studies are prone to 19 
significant biases both in case selection, favouring the inclusion of those with more severe 20 
cirrhosis, and with respect to HCC ascertainment, employing active case finding.  Recently, 21 
Danish evidence derived from a large population based cohort reports 5-year cumulative 22 
incidence of only 1% in patients with cirrhosis of an alcoholic aetiology, with HCC barely 23 
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contributing to the high mortality seen in these patients14.  Many studies suggest that other 1 
aetiologies of cirrhosis, particularly viral hepatitis, carry a greater risk of HCC.  However, there 2 
is no study to date that has been able to accurately estimate the rate of HCC in patients with 3 
cirrhosis of varying aetiologies drawn from the same underlying population.  4 
    5 
We therefore carried out a comprehensive population based study of the risk of HCC in cirrhosis 6 
of all aetiologies with a view to improving the evidence-base through which recommendations to 7 
current HCC surveillance guidelines can be made to improve their cost effectiveness. 8 
 9 
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Methods 1 
We conducted a cohort study using linked data from three sources. The General Practice 2 
Research Database (GPRD; now the Clinical Practice Research Datalink - CPRD) is a 3 
prospectively gathered, anonymised primary care database using data from more than 600 GP 4 
practices in the UK, between 1987 to the present15. In brief, it provides all recorded primary care 5 
data on patients including clinical diagnoses, treatments, and outcomes. Its validity has been 6 
tested in numerous studies;  for example a systematic review of 357 validation studies showed 7 
that overall, a high proportion of cases were confirmed for all diseases with a median of 89%, i.e. 8 
89 of 100 cases with a computerized diagnosis were confirmed based on additional internal or 9 
external information16.  Cancer diagnoses specifically have been validated directly against cancer 10 
registration information giving positive predictive values of a GPRD cancer diagnosis of 96% for 11 
lung cancer, 92% for urinary tract cancer, 97% for gastro-oesophageal cancer and 98% for 12 
colorectal cancer17. Hospital Episodes Statistics (HES) is a secondary care database containing 13 
data for all hospitalizations in England, including diagnoses and procedures. 51% of English 14 
GPRD practices are linked to HES, from April 1997 onwards.  Cancer registry data are provided 15 
by the National Cancer Intelligence Network and consist of two databases; the Merged Cancer 16 
Registry data (1990 to 2006, from English registries only) and the Office for National Statistics 17 
(ONS) minimum cancer dataset (1971 to 2006).   18 
 19 
We identified people with cirrhosis of the liver from subjects in the whole GPRD who had their 20 
first incident recording of cirrhosis, oesophageal varices or portal hypertension within their up to 21 
research standard GPRD data between 1987 and 2006 as we have previously described18.  In this 22 
previous study we carried out a validation of the diagnosis in which, in order to assess the 23 
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accuracy of the recording of the diagnosis of cirrhosis, paper records from the GPs were 1 
requested from a stratified random sample of patients with a diagnostic or therapeutic code for 2 
cirrhosis. The patients’ paper records (that includes letters from Consultant Hepatologists, liver 3 
biopsy results etc) were examined by a consultant hepatologist (GPA). Information was gathered 4 
on whether there was any record of cirrhosis, whether this had been confirmed by biopsy and 5 
whether there was any record of presumed aetiology of the cirrhosis. Three-quarters of these 6 
patients had definite evidence of cirrhosis in the available paper records.  Of the 25% of cases 7 
where cirrhosis could not be confirmed, all bar one had evidence of chronic liver disease; they 8 
were cases of PBC, alcoholic liver disease, Budd-Chari syndrome and autoimmune hepatitis. In 9 
subsequent work we have demonstrated that approximately three quarters of those people with a 10 
diagnosis of cirrhosis in their primary care record have an inpatient hospitalisation related to 11 
cirrhosis19.  Given that there is a reasonably high proportion of cases identified at a compensated 12 
stage of their disease and not all patients will require inpatient hospitalization this provides 13 
further evidence of the robustness our definition. 14 
 15 
We then restricted our population to only those who were registered in practices with linked 16 
cancer registry data.  Presumed aetiology of cirrhosis of either alcohol-related, viral hepatitis (B 17 
and C), autoimmune or metabolic liver disease (i.e. PBC, haemochromatosis, alpha-1 anti-trypsin 18 
deficiency) or other unspecified causes of cirrhosis was defined using appropriate Read codes for 19 
these aetiologies.  We also used information in the available laboratory results (for example 20 
hepatitis B and C positive results, anti-mitochondrial antibody) and linked Hospital Episodes 21 
Statistics (using International Classification of Diseases (ICD) 10 codes)20. We defined excess 22 
alcohol use if there was evidence in the primary or secondary care records of evidence of for 23 
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example alcohol abuse, addiction or dependence, ‘problem drinking’ or referral to alcohol 1 
cessation services.  Similarly if the weekly alcohol consumption in their primary care records 2 
exceeded the Chief Medical Officer’s recommended amount (14 units for women, 21 units for 3 
men) these patients were ascribed as having alcohol-related cirrhosis.  Aetiologies were assigned 4 
in a hierarchical fashion ordered chronic viral hepatitis, autoimmune disease, metabolic disease 5 
and alcohol excess.  Those without any of these aetiologies were grouped together as cryptogenic 6 
cirrhosis. Once categorized, these groups were considered mutually exclusive for analysis 7 
purposes.    8 
 9 
We identified people with HCC using the linked cancer registry data (data available from 1971 – 10 
2006) using ICD 10 and ICD10-O-3 oncology codes20. Where necessary ICD921 codes were 11 
mapped to ICD10.  We defined incident HCC as the first occurrence of a record in cancer 12 
registry data of a diagnosis coded with a 4 character ICD10 code of C22.0 (malignant neoplasm, 13 
liver cell carcinoma) coupled with a histological classification of either 81703 (hepatocellular 14 
carcinoma NOS) or 80003 (neoplasm, malignant) in ICD-O-3.   15 
 16 
Statistical analysis 17 
Person-time at risk commenced at the first record of cirrhosis in the people with cirrhosis and 18 
ended when patients left a participating GP practice or died or the end of cancer registration 19 
follow up (31st December 2006) or when liver transplant occurred, whichever came first.  We 20 
assessed several baseline characteristics including whether the person with cirrhosis had 21 
evidence of decompensation (prior to and up to 30 days after entry) or diabetes mellitus.  22 
Incidence rates of HCC were calculated by dividing the number of cases of HCC by total person 23 
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years of follow-up and are presented per 1000 person years with 95% confidence intervals.  1 
Hazard ratios for HCC were estimated comparing incidence rates by presumed aetiology using 2 
Cox proportional hazard’s regression adjusted for sex and age at the start of follow up, smoking 3 
status, body mass index (BMI) and presence of diabetes mellitus, extracted prior to start of 4 
follow up in the study.  Model assumptions were checked by plotting proportional hazard and log 5 
minus log plots.  We fitted a semiparametric proportional hazards model (Fine-Gray method22, 23) 6 
to estimate the predicted cumulative incidence function for occurrence of HCC accounting for 7 
the competing risks of death from any cause and liver transplant.  These estimates were 8 
calculated at the mean value of all covariates in the model (age, sex, BMI, smoking status and 9 
diabetes mellitus) except the primary exposure i.e. aetiology of cirrhosis.   All data management 10 
and statistical analysis were performed using Stata 14 MP2 (Statacorp, 4905 Lakeway Drive, 11 
College Station, Texas 77845 USA).  12 
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Results 1 
We identified 3,107 people with cirrhosis from practices with linked cancer registry data 2 
available.  These subjects contributed 12977 person years respectively to the analyses. Of the 3 
people with cirrhosis, 56% were classified as having a presumed aetiology of alcohol, 4 
approximately 12% chronic viral hepatitis, 11% autoimmune or metabolic disease and the rest 5 
(21%) were classified as cryptogenic.  Baseline characteristics such as age and sex varied 6 
statistically depending on which aetiology category people were in (table 1).  This was also true 7 
of all the other factors we measured.  As expected, the aetiology with the greatest proportion of 8 
those with decompensation was alcohol, and in those with diabetes cryptogenic.  More 9 
transplants occurred during follow up in those with chronic viral hepatitis than any other group 10 
whereas more deaths occurred in the alcohol and cryptogenic groups compared to the others. 11 
 12 
Absolute rate of HCC and variation with aetiology 13 
There were 51 incident cases of HCC in the whole population.  Overall the incidence rate among 14 
people with cirrhosis of all causes was 3.9 per 1000 person years or on average 0.4% per annum.  15 
Absolute rates of HCC varied by age, sex and aetiology of disease and are displayed in table 2.  16 
As expected they were higher in men compared to women, at older ages and among those with a 17 
chronic viral aetiology.  When mutually adjusted for age, sex, smoking status, BMI, diabetes 18 
mellitus and aetiology using a Cox proportional hazards model people with a chronic viral 19 
aetiology were 3 times more likely (HR 3.22 95% CI 1.56-6.65) to develop HCC than those with 20 
alcohol related cirrhosis.  Those with metabolic or autoimmune diseases were also at increased 21 
risk compared to the alcohol group whereas those with the assignation of cryptogenic cirrhosis 22 
had a similar incidence of HCC to the alcohol group.   23 
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 1 
Estimated predicted cumulative incidence of HCC by aetiology after accounting for 2 
competing risks 3 
The estimated predicted cumulative incidence of HCC at 1, 5 and 10-years by aetiology among 4 
the people with cirrhosis is shown in table 3.  For alcohol and cryptogenic aetiology the 10-year 5 
risk was less than 2%.  The cumulative incidence functions for each aetiology are shown in 6 
figure 1. 7 
 8 
 9 
 10 
 11 
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Discussion 1 
In this study we have quantified the 10-year cumulative incidence of HCC among people with 2 
cirrhosis of the liver resulting from alcohol excess; chronic viral hepatitis; autoimmune or 3 
metabolic diseases; or of unknown cause using a large, representative, population based cohort 4 
study.  Overall the incidence of HCC in all these groups was low regardless of aetiology.  We 5 
found the highest 10-year cumulative incidence of HCC among those with cirrhosis due to 6 
chronic viral hepatitis; people with either chronic viral hepatitis or autoimmune/metabolic 7 
diseases underlying their cirrhosis had a 2-3 fold increased risk of HCC compared to those with 8 
alcoholic cirrhosis.  However, in those people we identified as having alcohol as the presumed 9 
cause of their cirrhosis or no specific cause (i.e. cryptogenic cirrhosis) the 10-year cumulative 10 
incidence rates were less than 2% indicating that surveillance for HCC in these particular groups 11 
is unlikely to be cost-effective regardless of other parameters that could influence its cost or 12 
outcome. 13 
 14 
Strengths and limitations 15 
If there is imprecision in our definition of cirrhosis, the presumed aetiology we have ascribed or 16 
the ascertainment of incident HCC our results may be incorrect to some extent.  If we have either 17 
included people without cirrhosis in our disease cohort or missed people with the disease we may 18 
have respectively overestimated or underestimated the incidence of HCC.  For example, if we 19 
have included patients with alcoholic hepatitis or non-alcoholic steatohepatitis incorrectly as 20 
having cirrhosis when they don’t, we will have underestimated the incidence of HCC in the 21 
alcohol and cryptogenic group respectively.  For the definition of cirrhosis we have relied upon 22 
the accuracy of recording made by primary care physicians in the electronic health records of 23 
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their patients following communication from hepatologists in secondary care about the diagnosis 1 
of cirrhosis the latter have made.  We have previously validated this approach18 and shown that it 2 
is reliable. In this the recording of cirrhosis mirrors that of a number of other chronic diseases for 3 
which validation studies have been conducted16.  In addition to this, our cohort is of roughly the 4 
same age and sex distribution as those reported previously from similar population based or 5 
hospital registries from England, Denmark and Sweden14, 24-26. For these reasons we think it 6 
unlikely we have included many subjects without cirrhosis in our cirrhosis cohort.  It is possible 7 
however that those people diagnosed with decompensated alcoholic cirrhosis via an emergency 8 
admission to hospital who then died rapidly while an inpatient may not have had their diagnosis 9 
transmitted to primary care for retrospective addition to their records. By this mechanism we 10 
might fail to include some cases of cirrhosis.  In the context of our study, i.e. determining the risk 11 
of HCC for the purposes of deciding whether or not to carry out surveillance among people with 12 
alcoholic cirrhosis, the impact of having potentially excluded these individuals is minimal as 13 
they would contribute very little person time at risk and few events during their subsequent 14 
follow-up time under surveillance.  For the presumed aetiology of disease we have 15 
comprehensively searched the primary and secondary care electronic records of the people with 16 
cirrhosis which include not only diagnostic and procedure records but also, where available, 17 
laboratory and test results.  However, we must acknowledge that small variations in the number 18 
of cancers diagnosed among each of the aetiologies of liver disease due to misclassification of 19 
the aetiology could have led to some differences in our findings.  However, with respect to the 20 
classification of aetiology, our approach is similar if not more comprehensive than previous 21 
work. For example, our ascertainment of excess alcohol use is likely to have been more 22 
comprehensive than studies reliant solely on secondary care data.  Despite the challenges of 23 
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assigning aetiology our distribution of the aetiology of cirrhosis is very similar to that reported 1 
from northern European countries that have assembled similar cohorts.  By assuming that where 2 
a specific aetiology is recorded, for example autoimmune liver disease, that it is solely the cause 3 
of cirrhosis in a hierarchical manner we will have inevitably introduced some misclassification.  4 
We have chosen to do this purposefully as despite the large size of our cohort it is not large 5 
enough to permit us to determine precise rates of HCC among those with multiple aetiologies 6 
(for example those with a recording of both alcohol excess and an autoimmune liver disease).  7 
The effect of our mutually exclusive categorization is that the rates we have provided may be 8 
overestimates of the risk in those with a single aetiology further up our hierarchy if, as has been 9 
suggested, those with more than one aetiology have an increased risk25, 27. For the ascertainment 10 
of incident HCC we have used the linked national cancer registry data which is a method 11 
analogous to that carried out in previous reports from Sweden and Denmark14, 25.  We have used 12 
a specific ICD 10 code for HCC coupled with an oncology classification of histology in our 13 
definition to avoid, as far as possible, misclassification of, for example, metastatic liver cancer or 14 
cholangiocarcinoma which can otherwise occur28, 29 15 
 16 
We were able to adjust for some important confounders (smoking status, BMI and diabetes 17 
mellitus30, 31) in our multivariate Cox regression model but we did not have good data available 18 
on other potential confounding factors such as ethnicity which may have led to some residual 19 
confounding being present by this covariate.  In addition, due to the small numbers of events 20 
within each mutually exclusive aetiological category, we were unable to present meaningful 21 
stratified cumulative incidence rates by any of these covariates to assess for evidence of 22 
interactions.  We have however taken account of the potential competing risks of death from any 23 
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cause and liver transplant on the incidence of HCC via the predicted cumulative incidence 1 
function estimated in our analysis. 2 
 3 
Other literature 4 
Few studies have been able to study the risk of HCC for these aetiologies among one cohort 5 
identified from the same population based source in the manner that we have.  The best data for 6 
comparison we believe are those derived from the Swedish and Danish registry studies.  In 1998 7 
Sørensen et al reported HCC risks among people with cirrhosis diagnosed in Denmark between 8 
1977 and 1989 of alcoholic, chronic hepatitis, PBC and cryptogenic aetiologies24.  Their 9 
approximate crude rates for both alcohol and cryptogenic cirrhosis appear fairly similar to ours 10 
(3.4 and 2.5 per 1000 person years respectively).  In addition, a more recent analysis of the same 11 
data but limited to patients with alcoholic cirrhosis diagnosed between 1993 and 2005 by Jepsen 12 
et al., reported annual and cumulative 5 year incidence rates of 0.4% (95% CI 0.34%-0.47%) and 13 
1% (95% CI 0.8%-1.8%) respectively having excluded the first year of follow up14.  Kuper et al., 14 
carried out a similar study using Swedish data and reported cumulative 15 year risks of HCC of 15 
6.2% (95% CI 1%-12.5%) for those with chronic viral hepatitis and 1.1% (95% CI 0.8%-1.5%) 16 
for those with alcoholic cirrhosis25.  Studies from elsewhere in Europe, Japan and the United 17 
States of America have all reported higher rates of HCC for the same aetiologies we have 18 
examined9-13.  This is probably partly due to differences in the selection of their cohorts (all 19 
being clinic based and therefore likely to have selected more severe cases of cirrhosis), and/ or a 20 
differing distribution of aetiology of cirrhosis in those countries, favoring populations with HBV 21 
and HCV-related cirrhosis.  On this latter point our findings may not be so generalizable to some 22 
geographical areas due to their different case-mix of cirrhosis in terms of severity of disease at 23 
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diagnosis, quantity of alcohol consumption and underlying prevalence of diseases such as non-1 
alcoholic fatty liver disease. 2 
 3 
Clinical implications 4 
Our study contributes important information to the ongoing debate about the utility and 5 
implementation of surveillance for HCC among people with cirrhosis2, 3, 8.  In the AASLD 6 
guidelines on this subject7 it is stated that “for patients with cirrhosis of varying aetiologies, 7 
surveillance should be offered when the risk of HCC is 1.5% per year or greater” based on cost-8 
effectiveness modelling4-6.  In the United Kingdom a Health Technology Assessment economic 9 
model32 found that annual surveillance with a willingness to pay threshold of £30,000 per 10 
Quality Adjusted Life Year was only just cost-effective for alcoholic liver disease.  Given that 11 
our study has found far lower risks of HCC than were used in these economic models it seems 12 
highly likely that if they were repeated they would find that surveillance was not cost-effective.  13 
Though there may be particular patients with combinations of risk factors where surveillance is 14 
warranted our results imply that universal surveillance should not be undertaken on the basis of 15 
alcoholic aetiology or in cryptogenic cirrhosis and is likely to be of debatable value in 16 
autoimmune and metabolic causes of cirrhosis. 17 
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Figure Legends. Figure 1. Estimated predicted cumulative incidence (cumulative proportion with HCC 1 
during follow up) for HCC in the cirrhosis cohort by aetiology 2 
Tables.  3 
Table 1. Baseline characterstics, follow up and events among the cirrhosis cohort, presented by 4 
aetiology group (n=3107) 5 
  
Viral 
Hepatitis Autoimmune/metabolic Alcohol Cryptogenic 
Chi 
Squared 
Total number 374 343 1,743 647 
 % Aetiology 12.0 11.0 56.1 20.8 
 Median Follow up, years 2.6 3.1 2.6 3.0 
 Follow up IQR, years 5.0 5.1 4.9 5.6 
 Male 61.5 32.1 65.5 47.8 <0.001 
Age  
 18- 27.3 10.2 18.7 10.4 
 45- 34.5 19.2 28.9 12.4 
 55- 20.6 26.2 30.6 21.0 
 65- 17.7 44.3 21.9 56.3 <0.001 
BMI categories 
 <25 30.0 28.6 25.7 20.4 
 >=25 to 30 23.3 26.5 20.4 22.3 
 >=30 12.8 12.0 12.3 15.9 
 Missing 34.0 32.9 41.6 41.4 <0.001 
Smoking status 
 Current 35.0 16.0 39.8 13.8 
 Ex 11.2 18.1 11.2 15.6 
 No 28.9 42.3 19.3 36.6 
 Missing 24.9 23.6 29.8 34.0 <0.001 
Diabetes mellitus 13.6 11.1 13.0 20.1 <0.001 
Decompensated at start of follow 
up 30.8 23.0 35.6 18.7 <0.001 
Events 
 None 65.8 61.5 57.3 55.5 
 Hepatocellular carcinoma 3.2 2.3 1.3 1.4 
 Death 27.3 33.5 40.9 42.7 
 Liver transplant 3.7 2.6 0.6 0.5 <0.001 
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Table 2. Absolute incidence rates of HCC for all follow up time and Hazard Ratios (for HCC incidence) and their 95% confidence intervals for 1 
the cirrhosis cohort by age, sex and aetiology 2 
  
HCCs during follow 
up 
Person 
years 
Incidence rate per 1000  
person years (95% CI) 
Hazard Ratio 
(95% CI) 
Sex 
 Male 42 7,146 5.9 (4.3-8.0) 1 
 Female 9 5,831 1.5 (0.8-3.0) 0.2 (0.10-0.44) 
Age groups 
 18-44 years 6 2,390 2.5 (1.1-5.6) 1 
 45-54 years 9 3,292 2.7 (1.4-5.2) 0.85 (0.30-2.41) 
55-64 years 13 3,674 3.5 (2.1-6.1) 1.27 (0.47-3.42) 
65+ years 23 3,621 6.4 (4.2-9.6) 2.73 (1.05-7.10) 
Aetiology 
 Alcohol 22 6,977 3.2 (2.1-4.8) 1 
 Chronic viral hepatitis 12 1,572 7.6 (4.3-13.4) 3.22 (1.56-6.65) 
Autoimmune and metabolic diseases 8 1,520 5.3 (2.6-10.5) 2.7 (1.15-6.30) 
Cryptogenic 9 2,908 3.1 (1.6-5.9) 0.92 (0.42-2.05) 
 3 
* adjusted for sex, age groups, smoking status, BMI, diabetes mellitus and aetiology 4 
  5 
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Table 3. Estimated cumulative incidence (%) of HCC accounting for competing risks of death and liver 1 
transplant by aetiology at 1, 5 and 10-years of follow up 2 
Follow time (years) Viral Hepatitis Autoimmune/metabolic Alcohol Cryptogenic 
1 1.0 0.8 0.3 0.3 
5 2.8 2.3 0.9 0.8 
10 4.0 3.2 1.2 1.1 
 3 
  4 
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 1 
 2 
 3 
Footnote: Viral hepatitis = hepatitis B or C; Auto/Meta = Autoimmune or metabolic liver 4 
disease; Alcohol = alcoholic; Cryptogenic = no other distinct aetiology identified.  Values on 5 
the y axis represent proportions i.e. the risk of HCC at 10 years of follow up among those 6 
people with cirrhosis with chronic viral hepatitis (B or C) is 4%  7 
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Limitations 19 Discuss limitations of the study, taking into account sources of potential 
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Figure 1. Estimated predicted cumulative incidence (cumulative proportion with HCC during follow up) for 
HCC in the cirrhosis cohort by aetiology  
figure 1  
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